Management of schizophrenia with obesity, metabolic, and endocrinological disorders / Palmiero Monteleone en Psychiatric Clinics of North America, Año 2009 - Vol.32 No. 4 (Diciembre)

Público ISBD [artículo]  inPsychiatric Clinics of North America > Año 2009 - Vol.32 No. 4 (Diciembre) . - pp. 775-794 Título : Management of schizophrenia with obesity, metabolic, and endocrinological disorders Tipo de documento: texto impreso Autores: Palmiero Monteleone, Autor ; Vassilis Martiadis, Autor ; Mario Maj, Autor Fecha de publicación: 2020 Artículo en la página: pp. 775-794 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esquizofrenia, Obesidad, Diabetes, Síndrome metabólico, Hiperprolactinemia Resumen: People with schizophrenia have an increased prevalence of overweight/obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome, which increases the risk for cardiovascular diseases and mortality. Part of this increased risk is attributable to the use of antipsychotic medications, especially second-generation antipsychotics. Link: ./index.php?lvl=notice_display&id=24443 [artículo] Management of schizophrenia with obesity, metabolic, and endocrinological disorders [texto impreso] / Palmiero Monteleone, Autor ; Vassilis Martiadis, Autor ; Mario Maj, Autor . - 2020 . - pp. 775-794. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Psychiatric Clinics of North America > Año 2009 - Vol.32 No. 4 (Diciembre) . - pp. 775-794 Palabras clave: Esquizofrenia, Obesidad, Diabetes, Síndrome metabólico, Hiperprolactinemia Resumen: People with schizophrenia have an increased prevalence of overweight/obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome, which increases the risk for cardiovascular diseases and mortality. Part of this increased risk is attributable to the use of antipsychotic medications, especially second-generation antipsychotics. Link: ./index.php?lvl=notice_display&id=24443

---

1 (1 - 1 / 1)